KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 6

MEditerranean FeVer ( MEFV ) gene mutations in glomerulonephritides: a clinicopathological study

Ufuk İLGEN
Gökhan NERGİZOĞLU
Sayfa
1182–1191
Yayın Tarihi
2018-12-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The M694V mutation was more frequent in patients who needed chronic R RT.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: The aim of this study is to determine the ME diterranean F e V er ( MEFV ) gene mutation carrier rate in patients with glomerulonephritis and to investigate the association between disease features and MEFV variants.
📊
Temel Bulgular & Veri:Materials and methods: Medical records regarding clinical, laboratory, histopathological, and prognostic features of 200 adult patients with biopsy-proven glomerulonephritis were evaluated retrospectively.
💡
Sonuç & Katkı:The M694V mutation was more frequent in patients who needed chronic R RT.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:MEFV gene · mutation · glomerulonephritis

Abstract

Background/aim: The aim of this study is to determine the ME diterranean F e V er ( MEFV ) gene mutation carrier rate in patients with glomerulonephritis and to investigate the association between disease features and MEFV variants. Materials and methods: Medical records regarding clinical, laboratory, histopathological, and prognostic features of 200 adult patients with biopsy-proven glomerulonephritis were evaluated retrospectively. Exons 2 and 10 of the MEFV gene of each patient were sequenced by next-generation sequencing. Variants were detected and compared with disease features. Results: MEFV mutation carrier rate was 25%, similar among disease subgroups, and higher than the previously reported rates for normal populations. Demographic, clinical, and laboratory features at diagnosis did not differ in patients with and without mutations. Refractory disease rates were 73% and 40% in carriers and noncarriers of E148Q (P = 0.051). Percentage of global sclerotic glomeruli was higher in M694V carriers than noncarriers (medians 24% vs. 0%, P = 0.047). Tubulointerstitial fibrosis was also more severe in M694V carriers. The carrier rate of M694V was 14.3% in patients eventually needing chronic renal replacement therapy (RRT) (n = 21), whereas it was 2.8% in the group without RRT (OR = 5.8 [1.28-26.3], P = 0.040). Conclusion: MEFV mutation carrier rate was higher than expected in our sample of Turkish patients with glomerulonephritis. The E148Q mutation may be associated with refractory disease. The M694V mutation was more frequent in patients who needed chronic R RT.

🔖

Bu Makaleye Atıf Yap

İLGEN, U., NERGİZOĞLU, G. (2018). MEditerranean FeVer ( MEFV ) gene mutations in glomerulonephritides: a clinicopathological study. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 6, 1182–1191. https://ajindex.com/articles/113847

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Manukyan G, Aminov R. Update on pyrin functions and mechanisms of familial mediterranean fever. Front Microbiol 2016; 7: 456. Simon A, van der Meer JWM, Drenth JPM. Familial autoinflammatory syndromes. In: Firestein G, Budd R, Gabriel SE, McInnes IB, O’Dell J, editors. Kelley’s Textbook of Rheumatology. 9th ed. Philadelphia, PA, USA: Elsevier Saunders; 2012. pp. 1597-1615. [No authors listed.] Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997; 90: 797-807.
  2. Kasifoglu T, Calisir C, Cansu DU, Korkmaz C. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol 2009; 28: 41-46.
  3. Aksu K, Keser G. Coexistence of vasculitides with familial Mediterranean fever. Rheumatol Int 2011; 31: 1263-1274.
  4. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, Tutar E, Ozen S, Topaloglu R, Yilmaz E et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84: 1-11.
  5. Ben-Chetrit E, Yazici H. Thoughts on the proposed links between Behcet’s disease and familial Mediterranean fever. Clin Exp Rheumatol 2002; 20: S1-2. Schwartz T, Langevitz P, Zemer D, Gazit E, Pras M, Livneh A. Behcet’s disease in familial Mediterranean fever: characterization of the association between the two diseases. Semin Arthritis Rheum 2000; 29: 286-295.
  6. Fidder HH, Chowers Y, Lidar M, Sternberg M, Langevitz P, Livneh A. Crohn disease in patients with familial Mediterranean fever. Medicine (Baltimore) 2002; 81: 411-416.
  7. Yahalom G, Kivity S, Lidar M, Vaknin-Dembinsky A, Karussis D, Flechter S, Ben-Chetrit E, Livneh A. Familial Mediterranean fever (FMF) and multiple sclerosis: an association study in one of the world’s largest FMF cohorts. Eur J Neurol 2011; 18: 1146- 1150. Kalyoncu M, Acar BC, Cakar N, Bakkaloglu A, Ozturk S, Dereli E, Tunca M, Kasapcopur O, Yalcinkaya F, Ozen S. Are carriers for MEFV mutations “healthy”? Clin Exp Rheumatol 2006; 24: S120-122. Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soytürk M, Akar S, Tunca M et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006; 45: 746-750.
  8. Durmus D, Alayli G, Cengiz K, Yigit S, Canturk F, Bagci H. Clinical significance of MEFV mut